Skip to content

Annex

Annex I. Twelve local indicators, global targets and the corresponding indicator measurement activities in Hong Kong for viral hepatitis elimination

Local Indicator & Definition WHO targets Data collection Provisional figures
  1. Prevalence of chronic HBV infection
Number of persons with chronic HBV infection1, divided by the number of persons (total population) 		- Population Health Survey by DH and literature review 7.2% (2016) [20]
6.4% (2016) [21]
  1. Prevalence of chronic HCV infection
Number of persons with chronic HCV infection2, divided by the number of persons (total population) 		- 0.5% (Anti-HCV+, 2016) [20]
0.3% (HCV RNA+, 2016) [20]
0.2% (HCV RNA+, 2015) [22]
  1. Coverage of timely hepatitis B vaccine birth dose (within 24 hours) and other interventions to prevent MTCT of HBV
Number of newborns receiving
  • timely birth dose of hepatitis B vaccine within 24 hours or
  • other interventions to prevent MTCT of HBV (e.g. administration of HBIG)
divided by the number of live births 		By 2020: 50% ;
By 2030: 90% 		Statistics on administration of timely hepatitis B vaccine birth dose, regularly collected by DH >95%3
  1. Coverage of the third dose of hepatitis B vaccine among infants
Number of infants (<12 months of age) who received the third dose of hepatitis B vaccine, divided by the number of infants (<12months of age in a year) surviving to age 1 year 		By 2020: 90% ;
By 2030: 90% 		Immunisation Survey on Preschool Children by DH as proxy Coverage
Pre-school children
99.7%in 2018 [89]
99.2% in 2015 [90]
Timeliness[89]
Local children:
6.2 (IQR 6.1-6.4) months
Non-local children:
6.4 (IQR 6.2-6.9) months
  1. People living with HCV and/or HBV diagnosed
Number of persons with chronic HBV and/or HCV infection who have been diagnosed, divided by the number of persons with chronic HBV and/or HCV infection 		By 2020: 30% ;
By 2030: 90% 		Population Health Survey by DH and estimation from clinical and laboratory records in HA -
  1. Treatment coverage for hepatitis B patients
Number of persons with chronic HBV infection1 who are currently receiving treatment, divided by the number of persons with chronic HBV infection 		80% of eligible persons with chronic HBV infection treated by 2030 Clinical, laboratory and prescription records in HA -
  1. Treatment initiation for hepatitis C patients
Number of persons already diagnosed with chronic HCV infection2 who initiated treatment during a specified time frame (e.g. 12 months), divided by the number of persons already diagnosed with chronic HCV infection2 for the specified time period (12 months) 		80% of eligible persons with chronic HCV infection treated by 2030 -
  1. Viral suppression for chronic hepatitis B patients treated
Number of patients with chronic HBV infection on treatment who have a suppressed viral load(VL)4, divided by the number of patients with chronic HBV infection on treatment and assessed for VL in the past 12 months 		- -
  1. Cure for chronic hepatitis C patients treated
Number of patients who completed HCV treatment and had a sustained virological response (SVR)5, divided by the number of patients who completed HCV treatment and were assessed for SVR 12-24 weeks after the end of treatment (in the past 12 months) 		- -
  1. Cumulated incidence of HBV infection in children 5 years of age
Number of survey children 5 years of age living with biomarkers of past or present infection and/or chronic infection, divided by the number of children aged 5 years of age in surveys 		By 2020: 30% reduction6;
By 2030: 90% reduction7
(as compared with the baseline number in 2015) 		Biomarker survey or mathematical modelling 0.78% (children aged 12 – 15 years in 2009) [18]
  1. Incidence of HCV infection
Total number of new infections with HCV8, divided by the total population minus people living with hepatitis C 		By 2020: 30% reduction;
By 2030: 90% reduction
(as compared with the baseline number in 2015) 		Modelling with inputs from repeated surveys, including Population Health Survey by DH and published studies among PWID and MSM Number of reported acute cases:
34 (2018)
18 (2017)
39 (2016)
14 (2015)
  1. Deaths attributable to HBV and HCV infection
Number of deaths from
  • hepatocellular carcinoma (HCC) (ICD-10 code C22.0),
  • cirrhosis (ICD-10 codes K74.3, K74.4, K74.5, K74.6) and
  • chronic liver diseases (ICD-10 codes K72–K75)
attributable to HBV and HCV infection 		By 2020: 10% reduction;
By 2030: 65% reduction
(as compared with the baseline number in 2015) 		Review of death statistics in DH to identify related deaths; Attributable fraction to HBV and HCV by reviewing their respective clinical and/or laboratory records in HA -

1 Defined by HBsAg-positive serological status
2 Defined as positive for HCV RNA or HCV Ag
3 WHO-UNICEF Joint Reporting Form (data for 2019)
4 HBV DNA not detectable, based on VL measurement in the past 12 months
5 Based on VL measurement 12-24 weeks after the end of treatment (in the past 12 months)
6 Equivalent to 1% prevalence of HBsAg among children
7 Equivalent to 0.1% prevalence of HBsAg among children
8 Defined as anti-HCV positive per year

Annex II. Steering Committee on Prevention and Control of Viral Hepatitis – terms of reference and membership

Terms of Reference

  1. To keep in view local and international developments in the prevention and control of viral hepatitis;
  2. To advise the Government on overall policy, targeted strategies, and effective resource allocation related to prevention and control of viral hepatitis with a view to formulating an Action Plan; and
  3. To conduct and coordinate monitoring and evaluation of viral hepatitis control as set out in the Action Plan, and recommend appropriate response.

Co-chairpersons

Dr. CHAN Hon-yee, Constance, JP
Dr. LEUNG Pak-yin, JP (till July 2019)
Dr. KO Pat-sing, Tony (since August 2019)

Members

Prof. CHAN Lik-yuen, Henry
Dr. CHAN Chi-wai, Rickjason (since April 2019)
Dr. CHAN Ming-wai, Angus
Dr. HO Ka-wai, Rita (till February 2019)
Dr. LO Yee-chi, Janice (till March 2019)
Dr. LO Yim-chong (since February 2019)
Dr. LAI Sik-to
Dr. LAO Wai-cheung
Prof. LAU Yu-lung
Prof. LEE Shui-shan
Dr. LEUNG Wai-yee, Nancy (till July 2020)
Dr. LEUNG Wing-cheong
Dr. TSANG Tak-yin, Owen
Prof. YUEN Man-fung

Ex-officio members

Dr. WONG Ka-hing, JP
Dr. CHUNG Kin-lai
Mr. CHAN Wai-kee, Howard, JP

Secretary

Dr. CHAN Chi-wai, Kenny (till November 2018)
Dr. LAM Kit-yi, Rebecca (since November 2018)

Annex III. Clinical Working Group –
terms of reference and membership

Terms of Reference

  1. To provide input to and implement the Hong Kong Action Plan for Prevention and Control of Viral Hepatitis;
  2. To review and evaluate the service load and gaps in diagnosis, treatment and monitoring; and strengthen related service provision and staff training for viral hepatitis;
  3. To oversee the effective linkage of persons with viral hepatitis to treatment and care; and
  4. To devise, evaluate, update and implement cost-effective management guidance and protocols for viral hepatitis.

Convenor

Dr LAU Ka-hin (since June 2019)
Dr SO Wing-yee (till June 2019)

Members

Dr. CHAN Chi-wai, Kenny
(till November 2018)
Dr. Chan Man-chi, Grace
(since May 2020)
Dr. CHAN Ming-wai, Angus
Dr. CHAN Pang-fai
Dr. FUNG Yan-yue, James
Dr. HUI Yee-tak
Dr. KAN Yee-ling, Elaine
Dr. KWAN Yat-wah, Mike
Mr. KWONG Yiu-sum, Benjamin
(till May 2020)
Dr. LAM Kit-yi, Rebecca
(since November 2018)
Dr. LAO Wai-cheung
Dr. LAW Chun-bon
(till December 2019)
Dr. WONG Han, Ann
Prof. WONG Wai-sun, Vincent

Co-opt members

Ms. CHEUNG Kar-yee, Celia
(till November 2019)
Mr. CHEUNG Tak-lun, Alan
(since November 2019)
Dr. FUNG Wai-kwan, Barbara
Dr. LEUNG Wing-cheong
Ms. TSUI Lai-hing, Eva
Dr. WOO Pao-sun, Pauline
(till August 2019)

Secretary

Ms. CHAN Sin-yee, May

Annex IV. Public Health Working Group –
terms of reference and membership

Terms of Reference

  1. To provide input to and implement the Hong Kong Action Plan for Prevention and Control of Viral Hepatitis;
  2. To evaluate, revise and strengthen surveillance of viral hepatitis in Hong Kong;
  3. To promote awareness and advise on screening of viral hepatitis for the public and healthcare providers;
  4. To assist in education programmes to update healthcare providers related to viral hepatitis; and
  5. To enlist and partner with community and professional stakeholders according to strategy consideration.

Convenor

Dr. CHAN Chi-wai, Kenny (till November 2018)
Dr. LAM Kit-yi, Rebecca (since November 2018)

Members

Dr. CHAN Chi-wai, Rickjason (since April 2019)
Dr. CHEN Hong (since December 2019)
Dr. LAU Ka-hin (since June 2019)
Dr. LEUNG Oi-shan, Joanna
Dr. LO Yee-chi, Janice (till March 2019)
Dr. SO Wing-yee (till June 2019)
Dr. TSANG Chiu-yin, Chester
Dr. WONG Miu-ling
Dr. WONG Tin-yau, Andrew (till December 2019)

Co-opt members

Ms. CHEUNG Kar-yee, Celia (till November 2019)
Mr. CHEUNG Tak-lun, Alan (since November 2019)
Dr. WOO Pao-sun, Pauline (till August 2019)

Secretary

Dr. KWOK Lai-key, Priscilla (since January 2019)
Dr. WONG Chun-kwan, Bonnie (till January 2019)